Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Urinary Bladder Neoplasms 5Melanoma 2Glioblastoma 2Brain Neoplasms 2Urothelial Carcinoma of the Bladder 1Squamous Cell Carcinoma of Head and Neck 1Oligodendroglioma 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoma, Follicular 1Laryngeal Neoplasms 1Glioma 1Ganglioneuroblastoma 1Craniopharyngioma 1Carcinoma 1Astrocytoma 1

Interventions

Gemcitabine 31Cisplatin 22pembrolizumab 21Magnetic Resonance Spectroscopy 18Specimen Handling 16durvalumab 11Mitomycin 10enfortumab vedotin 9avelumab 9Cystoscopy 9Nivolumab 8Fluorouracil 8Carboplatin 8Radiation 7Cystectomy 7atezolizumab 5Transurethral Resection of Bladder 5Radiotherapy 5Mitozytrex 5Immunoglobulin G 5Docetaxel 5Disulfides 5Biopsy 5tremelimumab 4sacituzumab govitecan 4erdafitinib 4dehydroftorafur 4Platinum 41,2-diaminocyclohexaneplatinum II citrate 4disitamab vedotin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Transurethral Resection of Bladder × 90 days × Clear all
NCT07000084 2026-06-02

GAIN-BCG

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
330 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
475 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07061964 2026-05-26

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
111 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

University of Washington

Phase 1/2 Not yet recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04164082 2026-05-13

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
161 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡